Abstract 4141518: Disparities in Associations Between Migraine and Cardiovascular Events: A Cross Sectional Cohort Study in the Veterans Health Administration
Abstract
The extent to which migraine is associated with cardiovascular events may differ across age, gender, racial and ethnic subgroups.
The current study uses the migraine cohort from the Headache Centers of Excellence VHA Headache Cohort. Migraine cases include veterans who had an International Classification of Disease-9/10 code of migraine in the VHA electronic health record between 2008-2023. Controls had no headache ever coded in their VHA electronic health record, and were matched on age, gender, race, ethnicity, and point of care the year of cohort entry (defined as the first year in which headache was diagnosed for the migraine group). Baseline cardiovascular events were extracted from the VHA electronic health record using validated algorithms from 6 months prior to cohort entry to 12 months following cohort entry. Separate logistic regression models evaluated the relationship between migraine vs. matched control and each cardiovascular outcome separately in the following subgroups: gender (men and women), age (18-49 and 50+), race (White and Black), and ethnicity (Non-Hispanic and Hispanic).
The cohort included 668,968 individuals with migraine and 1,337,937 non-headache controls. Overall, subgroup analyses found the strongest relationships between migraine (vs. matched control) and cardiovascular outcomes in younger adults (aged 18-49): ischemic stroke OR = 3.62, 95% CI = 3.33, 3.94; transient ischemic attack OR = 9.0, 95% CI = 7.65, 10.54; Notably, migraine was…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 668,968 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.